
ACT Brief: Community Research Financing Gaps, Neuroscience Endpoint Data, and Teva’s Biosimilar Deal
2026-11-04
0:00
1:57
In today’s ACT Brief, we examine why community research needs lasting financing and infrastructure, how electronic outcome tools can strengthen neuroscience endpoints, and how Teva is licensing two biosimilars from Samsung Bioepis.
Fler avsnitt från "Applied Clinical Trials"



Missa inte ett avsnitt av “Applied Clinical Trials” och prenumerera på det i GetPodcast-appen.








